Who
Jeffrey L. Ives
Director
Company insider
Files Form 4 as: Director, Acumen Pharmaceuticals; Director, Tvardi Therapeutics.
In numbers
- Trades disclosed
- 74
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $1.1M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 16 Jul 2014
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 4 Jun 2025filed 5 Jun 2025 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 4 Jun 2025filed 5 Jun 2025 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,800 at $0.00 | filing |
| 10 Jun 2024filed 10 Jun 2024 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | TVRD Tvardi TherapeuticsBiotechnology | SEC FORM 4 Code A | —150,647 at $0.00 | filing |
| 17 Aug 2023filed 18 Aug 2023 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,149 at $0.00 | filing |
| 17 Aug 2023filed 18 Aug 2023 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,800 at $0.00 | filing |
| 17 Aug 2023filed 18 Aug 2023 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $28K39,149 at $0.72 | filing |
| 17 Aug 2023filed 18 Aug 2023 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $254K39,149 at $6.48 | filing |
| 17 Aug 2023filed 18 Aug 2023 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3,3322,800 at $1.19 | filing |
| 17 Aug 2023filed 18 Aug 2023 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $19K2,800 at $6.66 | filing |
| 6 Jun 2023filed 7 Jun 2023 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,961 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | TVRD Tvardi TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,362 at $0.00 | filing |
| 15 Jul 2022filed 19 Jul 2022 | TVRD Tvardi TherapeuticsBiotechnology | SEC FORM 4 Sold | $33K3,600 at $9.05 | filing |
| 15 Jun 2022filed 17 Jun 2022 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
Contrasting Phibro Animal Health (NASDAQ:PAHC) and Tvardi Therapeutics (NASDAQ:TVRD)TVRD · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Jeffrey L. Ives; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.